SEEL Seelos Therapeutics, Inc.

On January 25, 2019, Apricus Biosciences, Inc. (formerly Nasdaq: APRI) announced the signing of a definitive agreement to merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction. The merged company trades as the symbol SEEL and will focus on the development and commercialization of central nervous system (CNS) therapeutics with known mechanisms of action in areas with a highly unmet medical need. Upon completion of the proposed merger, the name of the merged company will be Seelos Therapeutics, Inc..

$4.87  -0.50 (-9.23%)
As of 05/10/2021 15:59:42 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1999
Outstanding shares:  78,583,021
Average volume:  3,510,474
Market cap:   $403,916,728
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    81577F109
ISIN:        US81577F1093
Sedol:      BFYVZ75
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   13.97
PS ratio:   0.00
Return on equity:   -134.83%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy